Article

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised Remains

2025-07-24

Abstract excerpt

<h4>Introduction</h4> SARS-CoV-2 virus inflicts a major ongoing medical toll via acute infection with substantial morbid and mortal outcomes, as well as post-acute sequelae. Multiple SARS-CoV-2 RBD-directed mAbs, which emulate native human immunobiology following infection, have been developed, authorized, and demonstrated substantial efficacy for treatment of COVID-19. However, rapid virus evolution challenges t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 40ee2698-f24a-5513-b8f8-07240acdf631
DOI: 10.1101/2025.07.23.25332095

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsDOI 10.1101/2025.07.23.25332095Read

A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19Semantic proximity Read

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity Read

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineagesSemantic proximity Read

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individualsSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

An Overview of the Immune Response to COVID-19 Vaccination and Strategies to Boost SARS-CoV-2 Immunity in People with Inborn Errors of ImmunitySemantic proximity Read

EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity Read

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity Read

COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Semantic proximity Read

DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Semantic proximity Read

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read

Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity Read